Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

SML0437

Sigma-Aldrich

Oxandrolon

≥98% (HPLC)

Synonym(e):

17β-Hydroxy-17α-methyl-2-oxa-5α-androstan-3-one, 8075CB, NSC 67068, Oxandren, Provitar, SC 11585, Vasorome

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C19H30O3
CAS-Nummer:
53-39-4
Molekulargewicht:
306.44
EG-Nummer:
200-172-9
MDL-Nummer:
MFCD00198944
UNSPSC-Code:
51111800
PubChem Substanz-ID:
329824720
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

powder

Optische Aktivität

[α]/D -19 to -26°, c = 1 (CDCl3)

Arzneimittelkontrolle

USDEA Schedule IIIN; regulated under CDSA - not available from Sigma-Aldrich Canada

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL (clear solution; warmed)

Lagertemp.

2-8°C

SMILES String

C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1

InChIKey

QSLJIVKCVHQPLV-PEMPUTJUSA-N

Angaben zum Gen

human ... AR(367)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Biochem./physiol. Wirkung

Oxandrolone is a synthetic anabolic steroid. It is is a non-aromatizable androgen with no estrogenic effects and with mild androgenic activity. Clinical uses of oxandrolone include to promote weight gain after weight loss following extensive surgery or chronic infections or trauma, to offset the protein catabolism associated with prolonged administration of corticosteroids, to relieve bone pain frequently accompanying osteoporosis, and to treat Turner′s syndrome in girls.

Leistungsmerkmale und Vorteile

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Piktogramme

Health hazard
GHS08

Signalwort

Danger

H-Sätze

H351,H360FD

Gefahreneinstufungen

Carc. 2 - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 2

1 of 2

Metformin -hydrochlorid British Pharmacopoeia (BP) Reference Standard

BP227

Metformin -hydrochlorid

Metformin -hydrochlorid Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1084

Metformin -hydrochlorid

Rhonda Orr et al.
Drugs, 64(7), 725-750 (2004-03-18)
There has been increasing interest in the development of effective agents that can be safely used to promote anabolism in the clinical setting for patients with chronic wasting conditions as well as in the prevention and treatment of frailty associated
Susan R Rose et al.
Pediatric blood & cancer, 61(1), 11-19 (2013-09-11)
A majority of Fanconi anemia (FA) patients will experience bone marrow failure (BMF) and androgen therapy (most often oxymetholone) may be utilized as a treatment to improve BMF-related cytopenias. However, oxymetholone is associated with toxicities making identification of other agents
Gerd G Gauglitz et al.
Current opinion in clinical nutrition and metabolic care, 14(2), 176-181 (2010-12-16)
The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and
Clinical practice. Short stature in childhood--challenges and choices.
David B Allen et al.
The New England journal of medicine, 368(13), 1220-1228 (2013-03-29)
Emma Jane Gault et al.
BMJ (Clinical research ed.), 342, d1980-d1980 (2011-04-16)
To examine the effect of oxandrolone and the timing of pubertal induction on final height in girls with Turner's syndrome receiving a standard dose of growth hormone. Randomised, double blind, placebo controlled trial. Setting 36 paediatric endocrinology departments in UK
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.